Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
Fu H, Sun X, Lin R, Wang Y, Xuan L, Yao H, Zhang Y, Mo X, Lv M, Zheng F, Kong J, Wang F, Yan C, Han T, Chen H, Chen Y, Tang F, Sun Y, Chen Y, Xu L, Liu K, Zhang X, Liu Q, Huang X, Zhang X.
Fu H, et al. Among authors: tang f.
BMC Med. 2024 Feb 27;22(1):85. doi: 10.1186/s12916-024-03275-5.
BMC Med. 2024.
PMID: 38413930
Free PMC article.
Clinical Trial.